Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03266627 · ClinicalTrials.gov registry record · Phase 2
Adenovirus-specific Cytotoxic T-lymphocytes for Refractory Adenovirus Infection
A Phase 2 study of Adenovirus and Primary Immune Deficiency Disorder, sponsored by New York Medical College.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 10
- Study locations
NCT03266627 is a Phase 2 study of Adenovirus and Primary Immune Deficiency Disorder that is actively recruiting participants, run by New York Medical College. The registered enrollment target is 20 participants, below the 28-participant average among 6 other Adenovirus trials with a reported enrollment target (29% lower). The trial reports 10 study locations across 8 states.
The verdict
NCT03266627, a Phase 2 study of Adenovirus and Primary Immune Deficiency Disorder, is actively recruiting participants, sponsored by New York Medical College.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 10
- Study locations
Study Summary
Related donor Adenovirus (ADV) specific cytotoxic T cells (CTLs) manufactured with the Miltenyi CliniMACS Prodigy Cytokine Capture System will be administered intravenously in in children, adolescents and young adults with refractory ADV infection post Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT), with primary immunodeficiencies (PID) or post solid organ transplant. Funding Source: FDA OOPD
Conditions Studied
Interventions
- DRUG cytotoxic t-lymphocytes
Study Locations (10)
California
- Children's Hospital Los Angeles - Los Angeles
- University of California San Francisco - San Francisco
Colorado
- Children's Hospital of Colorado - Aurora
- University of Colorado Denver - Aurora
Indiana
- Indiana University - Indianapolis
Maryland
- Johns Hopkins - Baltimore
Missouri
- Washington University - St Louis
Ohio
- Nationwide Children's Hosptial - Columbus
Pennsylvania
- Children's Hospital of Pennsylvania - Philadelphia
Wisconsin
- Medical College of Wisconsin/Children's Hospital of Wisconsin - Milwaukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2018-11-01 |
| Est. Completion | 2027-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03266627
The ClinicalTrials.gov registry entry for NCT03266627 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 28-participant average among 6 other Adenovirus trials with a reported enrollment target (29% lower). The listed sponsor is New York Medical College, which has 47 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Adenovirus appearing as the primary indexed condition, and to 1 intervention - of which cytotoxic t-lymphocytes is the first listed.
NCT03266627 reports 10 study locations spanning 8 distinct geographic areas - top geographies include California, Colorado, Indiana.
Frequently Asked Questions
What is clinical trial NCT03266627 about?
NCT03266627 is a clinical study titled "Adenovirus-specific Cytotoxic T-lymphocytes for Refractory Adenovirus Infection". Related donor Adenovirus (ADV) specific cytotoxic T cells (CTLs) manufactured with the Miltenyi CliniMACS Prodigy Cytokine Capture System will be administered intravenously in in children, adolescents and young adults with refractory ADV infection post Allogeneic Hematopoietic Stem Cell Transplantat...
What is the current status of trial NCT03266627?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2018-11-01. Estimated completion is 2027-12-31.
What conditions does trial NCT03266627 study?
This clinical trial studies the following conditions: Adenovirus, Primary Immune Deficiency Disorder.
What interventions are being tested in trial NCT03266627?
The interventions under investigation include: cytotoxic t-lymphocytes (DRUG).
Who is sponsoring clinical trial NCT03266627?
This trial is sponsored by New York Medical College, which has 47 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03266627 being conducted?
This trial has 10 study locations across California, Colorado, Indiana, Maryland, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Adenovirus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Haplo-identical Viral-Specific T-cells for Treatment of Cytomegalovirus and Adenovirus Infections After Hematopoietic Cell Transplantation
RECRUITING · Phase 2
-
R-MVST Cells for Treatment of Viral Infections
RECRUITING · Phase 1
-
Donor Virus-Specific CMV or AdV CTL to Treat CMV or AdV Reactivation or Disease After Solid Organ or HCT
RECRUITING · Early Phase 1
-
Viral Specific T-Lymphocytes to Treat Infection With Adenovirus, Cytomegalovirus or Epstein-Barr Virus in Patients With Compromised Immunity
RECRUITING · Phase 1
-
R-MVST Cells for Treatment of Viral Infections in Children and Young Adults
RECRUITING · Phase 1
-
Viral Specific T-Lymphocytes to Treat Adenovirus or CMV
ACTIVE NOT RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.